Case Report

Successfully Treated Calcific Uremic Arteriolopathy: Two Cases of a High Anion Gap Metabolic Acidosis with Intravenous Sodium Thiosulfate

Joshua L. Rein,1 Kana N. Miyata,1 Kobena A. Dadzie,2 Steven J. Gruber,2 Roxana Sulica,3 and James F. Winchester2

1 Department of Medicine, Mount Sinai Beth Israel, 350 E 17th Street, 20th Floor Baird Hall, New York, NY 10003, USA
2 Division of Nephrology and Hypertension, Mount Sinai Beth Israel, 350 E 17th Street, 18th Floor Baird Hall, New York, NY 10003, USA
3 Department of Pulmonary, Critical Care & Sleep Medicine, Mount Sinai Beth Israel, 7 Dazian Building, 1st Avenue at 16th Street, New York, NY 10003, USA

Correspondence should be addressed to Joshua L. Rein; josrein@chpnet.org

Received 17 July 2014; Revised 10 October 2014; Accepted 30 October 2014; Published 19 November 2014

Academic Editor: Vasant Sumethkul

Copyright © 2014 Joshua L. Rein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a rare but potentially fatal disorder associated with renal insufficiency. The condition is characterized by arteriolar calcification, thrombus formation, and distal ischemia and necrosis of the skin and subcutaneous tissue. Mortality is near 50% and is often due to ulcer-related sepsis. Risk factors include hypercalcemia, hyperphosphatemia, elevated calcium (Ca) and inorganic phosphorus (Pi) product, hyperparathyroidism, use of calcium-based phosphate binders, use of Vitamin D analogs, warfarin use or Vitamin K deficiency, female gender, peritoneal dialysis (PD), and Caucasian race [1].

Sodium thiosulfate (STS) has been traditionally used as an antidote for cyanide poisoning, cisplatin toxicity, and nephrocalcinosis. In 2004, Cicone et al. were the first to describe the successful use of STS for the treatment of calciphylaxis [2]. Since then, STS has been shown in numerous case reports to improve wound healing and diminish pain within days of initiation. We describe the successful use of intravenous STS for the treatment of CUA in two patients.

1. Introduction

Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a rare but potentially fatal disorder associated with renal insufficiency. The condition is characterized by arteriolar calcification, thrombus formation, and distal ischemia and necrosis of the skin and subcutaneous tissue. Mortality is near 50% and is often due to ulcer-related sepsis. Risk factors include hypercalcemia, hyperphosphatemia, elevated calcium (Ca) and inorganic phosphorus (Pi) product, hyperparathyroidism, use of calcium-based phosphate binders, use of Vitamin D analogs, warfarin use or Vitamin K deficiency, female gender, peritoneal dialysis (PD), and Caucasian race [1].

Sodium thiosulfate (STS) has been traditionally used as an antidote for cyanide poisoning, cisplatin toxicity, and nephrocalcinosis. In 2004, Cicone et al. were the first to describe the successful use of STS for the treatment of calciphylaxis [2]. Since then, STS has been shown in numerous case reports to improve wound healing and diminish pain within days of initiation. We describe the successful use of intravenous STS for the treatment of CUA in two patients.

2. Case Presentation

2.1. Case 1. A 49-year-old Caucasian female presented with multiple tender lower extremity lesions that progressed over seven months. Past medical history was significant for end stage renal disease (ESRD) on continuous ambulatory PD and severe idiopathic pulmonary arterial hypertension (IPAH) on epoprostenol and warfarin. A skin biopsy revealed metastatic calcification consistent with calcinosis cutis.

Upon presentation, physical exam showed severely painful, focal areas of necrosis surrounded by erythematous patches involving the proximal and distal upper and lower extremities (Figure 1). Laboratory studies were significant for Na 127 mmol/L, Cl 87 mmol/L, HCO3 25 mmol/L, BUN 16.8 mmol/L, Ca 1.9 mmol/L, Pi 1.8 mmol/L, Ca x Pi 3.4,
hemoglobin 95 g/L, albumin 3.3 μmol/L, and intact PTH 33.00 pmol/L. STS 25 g was administered daily intravenously (IV) and warfarin was discontinued. Shortly after the start of STS, there was rapid improvement in her pain as the wounds began to heal.

The patient continued STS IV after discharge and developed a severe anion gap metabolic acidosis (AGMA) (Na 139 mmol/L, Cl 81 mmol/L, HCO$_3$ 8 mmol/L, anion gap 50 mmol/L), which induced respiratory distress and a seizure. She was admitted to the intensive care unit where STS was held and sodium bicarbonate was administered. Serum bicarbonate level was normalized prior to restarting STS 12.5 g every other day. With the exception of nausea, the reduced dosing regimen was tolerated well with continued ulcer healing (Figure 1). At discharge, laboratory studies were notable for Na 135 mmol/L, Cl 91 mmol/L, HCO$_3$ 31 mmol/L, Ca 1.9 mmol/L, Pi 1.7 mmol/L, Ca × Pi 3.2, and albumin 3.2 μmol/L. After discharge, STS was continued at 12.5 g weekly for 4 months with complete healing. Sodium bicarbonate was continued at 1300 mg PO TID, titrated down, and eventually discontinued to maintain a serum bicarbonate level between 24 and 30 mmol/L. The patient died one year later from complications of IPAH.

2.2. Case 2. A 51-year-old morbidly obese Caucasian male presented with a one month history of multiple painful ulcers on his calves. Past medical history is significant for stage 5 chronic kidney disease secondary to NSAID nephropathy and glomerulonephritis requiring 6 years of hemodialysis (HD) that the patient self-discontinued 5 years prior to this admission. The patient was noncompliant with his home medications. Skin biopsy revealed endoluminal thrombogenic calcification involving small subcutaneous blood vessels and interstitial calcification of adipocytes.

On presentation, physical exam revealed a large ulceration of left forearm and multiple dry and tender necrotic ulcers of the distal lower extremities (Figure 2). Laboratory studies were significant for Na 138 mmol/L, Cl 105 mmol/L, HCO$_3$ 16 mmol/L, BUN 33.6 mmol/L, Ca 2.3 mmol/L, Pi 3.1 mmol/L, Ca × Pi 7.1, hemoglobin 78 g/L, albumin 4.9 μmol/L, and intact PTH 375.61 pmol/L. The patient progressed to ESRD and was started on HD. Serum bicarbonate level was normalized prior to beginning STS. 25 g IV was dosed after dialysis three times weekly with the development of an AGMA and tolerated without significant side effects (Na 137 mmol/L, Cl 92 mmol/L, HCO$_3$ 18 mmol/L, anion gap 27 mmol/L). Skin ulcerations showed significant healing and laboratory studies at discharge demonstrated Na 136 mmol/L, Cl 91 mmol/L, HCO$_3$ 21 mmol/L, Ca 1.8 mmol/L, Pi 2.2 mmol/L, Ca × Pi 4.0, and intact PTH 173.1 pmol/L. STS was continued after dialysis for 4 months ultimately with complete ulcer healing (Figure 2).

Figure 1: (a) Arm before treatment, (b) leg before treatment, (c) thighs before treatment, (d) left thigh 4 weeks after treatment, (e) right thigh with negative pressure dressing after 4 weeks of treatment, and (f) right thigh with negative pressure dressing after 8 weeks of treatment.
3. Discussion

We reported on 2 cases of CUA with AGMA from IV STS. Several prior case reports have described AGMA during STS treatment for CUA (Table 1) [2–6] with one leading to cardiac arrest from STS 25 g IV daily in a patient with CKD 4 [6]. Two patients with CKD 4 each received a cumulative dose of 25 g daily [5, 6]. Of ESRD patients, one was on PD and was treated with 25 g IV three times weekly; two patients were on HD and were treated, respectively, with 25 g IV three times weekly and 5 g IV four times weekly. All five cases were female and of the cases that specified race, all four were Caucasian. Although the incidence of STS induced AGMA is not well studied, one cohort demonstrated 4 of 27 (15%) calciphylaxis patients on HD who developed a high AGMA [7]. Dosing varied from 10 g IV three times weekly, 25 g IV three times weekly, and 25 g IV five times weekly. Interestingly, serum pH did not significantly differ between survivors and nonsurvivors. Another study of 172 CUA patients on HD showed a statistically significant rise in serum anion gap without a statistically significant change in serum sodium and bicarbonate levels before, during, and after STS therapy [8].

The means of STS inducing acidemia is unclear though possibly due to the retention of unmeasured sulfate anion and/or formation of thiosulfuric acid in blood [2, 4]. Additionally, an expansion acidosis may also occur due to the large sodium load, since sodium thiosulfate itself is not an acid [5]. Complicating the matter, STS can falsely increase the serum chloride measurement among certain laboratory analyzers, which can mask the presence of a high anion gap [9]. Therefore, serum pH should be monitored during treatment to avoid toxicity.

Figure 2: (a) Legs before treatment, (b) leg lesion after 12 weeks of treatment, (c) skin ulceration of forearm at beginning of treatment, and (d) skin ulceration of forearm after 8 weeks of treatment.
| Patient characteristics | Dose | Duration | Laboratory values | Outcome |
|-------------------------|------|----------|-------------------|---------|
| Cicone et al. 2004 [2]  | 69-year-old Caucasian female with ESRD on CAPD for 4 months. | 25 g IV 3x/week | 8 months | Average HCO$_3$ = 15.4 mmol/L, Average AG = 26.1 mmol/L | Resolution of pain and reduction in size of subcutaneous plaques. |
| Selk and Rodby 2011 [3] | 65-year old female with ESRD on HD. | 25 g IV 3x/week after HD | Not specified | HCO$_3$ = 10 mmol/L, AG = 44 mmol/L | Acidemia prompted a significant reduction in STS dose. CUA outcome not specified. |
| Bruculleri et al. 2005 [4] | 48-year-old Caucasian female with ESRD on HD. | 5 g IV 4x/week after HD | 34 months at time of publication. | Average HCO$_3$ = 13.1 mmol/L, Average AG = 26.7 mmol/L | Excellent wound healing without disease recurrence. |
| Vanparys et al. 2013 [5] | 71-year-old Caucasian female status, after cadaveric renal transplant with CKD 4 secondary to cyclosporine toxicity and chronic allograft dysfunction. | 12.5 g IV BID | 2 weeks | HCO$_3$ = 12 mmol/L, AG not specified | STS dose decreased to 7.5 g BID and PO bicarbonate started. Patient showed improved wound healing but died from sepsis. |
| Mao et al. 2013 [6] | 71-year-old Caucasian female with CKD 4. | 25 g IV daily | 2 weeks | Serum pH <6.80, HCO$_3$ = 6 mmol/L, AG = 45 mmol/L | Survived 2 cardiac arrests. Patient declined further treatment and was discharged to hospice. |
| Rein et al. (this report) | 49-year-old Caucasian female with ESRD on CAPD. | 25 g IV daily | 5 months | HCO$_3$ = 8 mmol/L, AG = 50 mmol/L | Dose changed to 12.5 mg IV every other day then 12.5 mg weekly. Cured of calciphylaxis in 5 months. |
| 51-year-old Caucasian male with ESRD started on HD. | 25 g IV 3x/week after HD | 4 months | HCO$_3$ = 18 mmol/L, AG = 27 mmol/L | No change in STS dose. Cured of calciphylaxis in 4 months. |
The mechanism of action of STS in treating CUA is not well established and likely multifactorial. The primary mechanism involves calcium chelation, as STS has been reported to react with calcium to form calcium thiosulfate, which is 250–100,000 times more soluble in aqueous solution than other calcium salts [10]. Additionally, STS demonstrates antioxidant properties that have been shown to improve endothelial dysfunction, promote vasodilation [11], and generate glutathione [3]. Interestingly, the observed acidemia with STS therapy may be an additional mechanism of action, inhibiting the precipitation of calcium and phosphate salts [11].

Thiosulfate has a renal clearance in dogs comparable to creatinine [12]. The half-life of IV thiosulfate in normal dogs was 46.8 minutes and prolonged to 239 minutes in anuric dogs with elevated plasma concentrations detected after at least 16 hours [13]. Lethal doses in animals have ranged from 1 to 4 g/kg and mortality is associated with acidemia, hypernatremia, hypoxia, and hypertension [14–15].

IV dosing for STS range from 5 to 75 g after HD and is most commonly given at 25 g three times weekly after HD with infusion times between 30 and 60 minutes [16]. Intrapерitoneal STS has been described in several reports at doses of 12.5 g–25 g in 2 L dialysate with varying PD intensity [17–19]. One case was complicated by chemical peritonitis [20] but argued that this adverse reaction was due to particulate matter contamination rather than STS [21]. No studies have analyzed the pharmacokinetics of STS with PD and two cases discuss pharmacokinetics with HD [11,16].

In Case 1, our initial regimen of 25 g IV daily was an aggressive attempt to achieve improved analgesia with cure of the disease. In retrospect, the time STS was administered each day was inconsistent, allowing for potential of overdose. If a relatively high dose or frequency is desired in PD patients, perhaps the acidemia could be remedied by infusing STS IV at the beginning of the nocturnal cycle, increasing exchange volumes, or the patient could be increased to 5–6 manual exchanges over 24 hours on days of administration to increase clearance.

Once again, STS is most commonly administered as 25 g IV three times weekly after HD. However, it is unknown whether a higher dose three times weekly after dialysis or a lower dose given daily is more effective and with less side effects. It seems reasonable to start at a lower dose of 12.5 g IV in HD and PD patients and up to 25 g IV in HD patients three times weekly. Dose titration should be performed through the duration of treatment to achieve a mild AGMA as the induced acidemia can augment the solubility of calcium and possibly aid in ulcer healing. Furthermore, dosing should be adjusted for changes in dialysis modality and intensity to achieve a therapeutic benefit and to avoid toxicity [7]. Currently, there is a scarcity of data regarding intraperitoneal dosing.

In conclusion, STS should be considered in the treatment of CUA. However, little is known about optimal dosing, pharmacokinetics, or adjustments for dialysis patterns and additional studies are required to determine dosing strategies to minimize severe potential side effects.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] R. Burnie, S. Smail, and M. M. Javaid, “Calciphylaxis and sodium thiosulphate: a glimmer of hope in desperate situation,” Journal of Renal Care, vol. 39, no. 2, pp. 71–76, 2013.
[2] J. S. Cicone, J. B. Petronis, C. D. Embert, and D. A. Spector, “Successful treatment of calciphylaxis with intravenous sodium thiosulfate,” American Journal of Kidney Diseases, vol. 43, no. 6, pp. 1104–1108, 2004.
[3] N. Selk and R. A. Rodby, “Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy,” Seminars in Dialysis, vol. 24, no. 1, pp. 85–88, 2011.
[4] M. Bruculleri, J. Cheigh, G. Bauer, and D. Serur, “Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis,” Seminars in Dialysis, vol. 18, no. 5, pp. 431–434, 2005.
[5] J. Vanparys, B. Sprangers, X. Sagaert, and D. R. Kuypers, “Chronic wounds in a kidney transplant recipient with moderate renal impairment,” Acta Clinica Belgica, vol. 68, no. 2, pp. 128–131, 2013.
[6] M. Mao, S. Lee, K. Kashani, R. Albright, and Q. Qian, “Severe anion gap acidosis associated with intravenous sodium thiosulfate administration,” Journal of Medical Toxicology, vol. 9, no. 3, pp. 274–277, 2013.
[7] E. Zitt, M. König, A. Vychytil et al., “Use of sodium thiosulfate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients,” Nephrology Dialysis Transplantation, vol. 28, no. 5, pp. 1232–1240, 2013.
[8] S. U. Nigwekar, S. M. Brunelli, D. Meade, W. Wang, J. Hymes, and E. Lacson Jr., “Sodium thiosulfate therapy for calcific uremic arteriolopathy,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 7, pp. 1162–1170, 2013.
[9] S. M. Wendroth, T. N. Heady, D. M. Havestick et al., “Falsely increased chloride and missed anion gap elevation during treatment with sodium thiosulfate,” Clinica Chimica Acta, vol. 431, pp. 77–79, 2014.
[10] H. Yatzidis, “Successful sodium thiosulfate treatment for recurrent calcium urolithiasis,” Clinical Nephrology, vol. 23, no. 2, pp. 63–67, 1985.
[11] S. Farese, E. Stauffer, R. Kalicki et al., “Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1447–1455, 2011.
[12] A. Gilman, F. S. Philips, and E. S. Koelle, “The renal clearance of thiosulfate with observations on its volume distribution,” The American Journal of Physiology, vol. 146, pp. 348–357, 1946.
[13] B. Braverman, A. D. Ivankovich, and G. Shah, “Thiosulfate pharmacokinetics in normal and anuric dogs,” Proceedings of the Society for Experimental Biology and Medicine, vol. 170, no. 3, pp. 273–280, 1982.
[14] D. L. Dennis and W. S. Fletcher, “Toxicity of sodium thiosulfate (NSC-45624), a nitrogen mustard antagonist, in the dog,” Cancer Chemotherapy Reports, vol. 50, no. 5, pp. 255–257, 1966.
[15] S. I. Baskin, A. M. Horowitz, and E. W. Nealley, “The antidotal action of sodium nitrite and sodium thiosulfate against cyanide
poisoning,” *Journal of Clinical Pharmacology*, vol. 32, no. 4, pp. 368–375, 1992.

[16] R. P. Singh, H. Derendorf, and E. A. Ross, “Simulation-based sodium thiosulfate dosing strategies for the treatment of Calciphylaxis,” *Clinical Journal of the American Society of Nephrology*, vol. 6, no. 5, pp. 1155–1159, 2011.

[17] D. Mataic and B. Bastani, “Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis,” *Renal Failure*, vol. 28, no. 4, pp. 361–363, 2006.

[18] N. New, J. Mohandas, G. T. John et al., “Calcific uremic arteriolopathy in peritoneal dialysis populations,” *International Journal of Nephrology*, vol. 2011, Article ID 982854, 9 pages, 2011.

[19] S. B. Dethloff, “Calcific uremic arteriolopathy: treatment with intraperitoneal sodium thiosulfate in a patient on peritoneal dialysis,” *Nephrology Nursing Journal*, vol. 39, no. 4, pp. 323–347, 2012.

[20] D. R. Gupta, H. Sangha, and R. Khanna, “Chemical peritonitis after intraperitoneal sodium thiosulfate,” *Peritoneal Dialysis International*, vol. 32, no. 2, pp. 220–222, 2012.

[21] C. Sherman, “Chemical peritonitis after intraperitoneal sodium thiosulfate,” *Peritoneal Dialysis International*, vol. 33, no. 1, p. 104, 2013.